After the long emergency we all took a breath and imagined that the worst was over. Unfortunately, this is not the case and we risk paying dearly for this choice.
The FDA has issued an Emergency Use Authorization (EUA) to a Clinical Decision Support System (CDSS) that provides when an adult patient hospitalized with COVID-19 is at risk of further complications.
Some healthcare organisations are using CRM systems to manage Covid-19 patients and suspicious cases.
Apple and Google are refining their COVID-19 contact tracing framework.
The FDA has authorized Abbott to market the BinaxNOW COVID-19 Ag CARD, a kit for the rapid diagnosis of Covid-19 through a nasal swab, for emergency use (EUA).
Imagine fighting current and future epidemics by delegating the collection and management of epidemiological data to local and regional health authorities and regions does not make sense: we need a common European action.
Brain Navi, a Taiwanese company, has developed a robot capable of performing nasal swabs.
The unprecedented crisis caused by the pandemic has triggered an acceleration of the spread of new digital tools.
Philips has introduced a new generation of wearable biosensors for early detection of deterioration of the patient’s clinical condition, including clinical surveillance for COVID-19.
The COVID-19 also affected the regulatory system of medical devices. In fact, in the face of the health emergency, the European Commission has presented a legislative proposal to postpone for one year the date of application of the new regulation on medical devices.